2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Plasma Cell Disorders, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

4750 Low-dose radiation delivered to the liver and spleen area ameliorates hemophagocytic lymphohistiocytosis in mice

Yijun Wu, MD, Xu Sun, PhD2, Kai Kang, MD3, Wenyi Liang, MD4, Weishi Cheng, MD5, Luocheng Zhang6, Yushuang Xiao7, Qiaolin Zhou, MD8, Yushu Zhong, MD9, Yang Dai, MD10, Ailin Zhao, PhD11, Ting Niu12
1 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
2 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
3 West China Hospital, Sichuan University., Chengdu, China
4 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
5 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
6 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
7 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
8 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China
9 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
10 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
11 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China
12 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University., Chengdu, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University., Chengdu, China

Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome driven by excessive immune activation, and effective targeted therapies remain limited. Low-dose radiation (LDR) is well recognized for its potent anti-inflammatory effects and has been successfully used in various non-malignant inflammatory disorders, such as degenerative joint diseases and severe pneumonia. Given the prominent hyperinflammatory state in the liver and spleen in HLH, this study aims to evaluate whether LDR directed to these organs can ameliorate disease manifestations and attenuate inflammation in HLH.

Methods: We used a primary HLH mouse model (Prf-/- mice infected with lymphocytic choriomeningitis virus). A dose-escalation study determined the safe and effective LDR regimen (0.5, 1 or 2 Gy/1f, 1f qd). After administering the optimal tolerated radiation dose, we assessed HLH-related clinical and immunological parameters and explored the underlying mechanisms.

Results: LDR delivered to the liver and spleen was well tolerated within the dose range, and the 2Gy*5f regimen produced optimal improvements in HLH-related clinical parameters. Specifically, it effectively reversed anemia (increased hemoglobin levels), markedly alleviated splenomegaly, reduced serum triglyceride levels, and downregulated classic HLH activity markers such as ferritin and soluble CD25 (sCD25). Histopathological analysis showed that LDR significantly reduced inflammatory injury in the liver. Multiplex cytokine profiling revealed that LDR broadly suppressed the hypercytokinemia characteristic of HLH, including IL-1β, TNF-α, GM-CSF, IFN-γ, IL-2, IL-4, IL-10, and chemokines such as CCL-3, CCL-4, CCL-5, CCL-20, and CCL-27. Preliminary mechanistic exploration suggested that the effect of LDR may be associated with a marked reduction of the aberrant expansion of CD86+ dendritic cells (DCs) in the mice, thereby contributing to the restoration of immune homeostasis.

Conclusions: This study provides the first preclinical evidence that LDR exerts significant therapeutic effects in HLH. By ameliorating anemia, reducing organ damage, and suppressing systemic inflammation, LDR shows unique therapeutic advantages and may represent a novel adjuvant or salvage strategy for HLH, warranting further translational research.

Yijun Wu, MD: No relevant conflicts of interest to declare.